Clinical Trial: A Study of the Concurrent Use of AGN-190584 and AGN-199201 in Participants With Presbyopia

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional

Official Title: A Phase 2, Multicenter, Double-masked, Randomized, Vehicle-Controlled, Study of the Concurrent Use of AGN-190584 and AGN-199201 in Patients With Presbyopia

Brief Summary: This study will identify the optimum concentrations of AGN-199201 and AGN-190584 when dosed in combination once a day for the improvement of uncorrected near visual acuity in participants with presbyopia (inability to focus on items close-up).

Detailed Summary:
Sponsor: Allergan

Current Primary Outcome: Weighted Average Change from Baseline in Uncorrected Near Visual Acuity (UNVA) Letters [ Time Frame: Baseline, Between hour 1 and hour 10 of each of the five 2-day dosing periods ]

Original Primary Outcome: Average Change from Baseline in Uncorrected Near Visual Acuity (UNVA) Letters [ Time Frame: Baseline, Between hour 1 and hour 10 of each of the five 3-day dosing periods ]

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Allergan

Dates:
Date Received: November 2, 2015
Date Started: April 29, 2016
Date Completion: August 13, 2017
Last Updated: May 17, 2017
Last Verified: April 2017